Eli Lilly and Company (LLY) Continued to Gain from Its Incretin Portfolio
Eli Lilly's incretin portfolio drives market share growth.
Eli Lilly and Company (LLY) continues to thrive, largely due to its incretin portfolio, which has propelled it to dominate the US market with 58% share and 71% of new prescriptions. The company recently reported Q3 results that exceeded analyst expectations, prompting a third increase in its annual guidance for 2026. With the anticipated launch of its oral GLP-1 drug, orforglipron, in Spring 2026, Eli Lilly is well-positioned for further growth.
Key Takeaways
- 1.
Eli Lilly commands 58% of the US incretin market and 71% of new prescriptions.
- 2.
The company raised its annual guidance for the third time in 2026.
- 3.
Eli Lilly's revenue increased by 45% to $65.2 billion in 2025.
Get your personalized feed
Trace groups the biggest stories, videos, and discussions into one feed so you can stay current without scanning ten tabs.
Try Trace free